



APRIL / 2020

## Fiocruz President talks about the arrival of the Covid-19 in Brazil



In an interview to the Fiocruz News Agency (AFN), Nisia Trindade Lima comments on the context of the Covid-19 pandemics and the challenges of its arrival in Brazil. The Fiocruz president also lists some of the actions taken by the institution as a response to this public health crisis, from the production of tests to health care to those infected. All departments and units of the Foundation are mobilized to face the epidemics. “It’s Fiocruz 120th anniversary in May, and it will be marked by our response to this pandemic, just like the origin of the institution was a public health response to epidemics in Rio de Janeiro”, highlights the president.

## Fiocruz builds new hospital center and invests in clinical trials with WHO



The rapid assembly unit will have 200 beds exclusively for intensive and semi-intensive care of critical patients infected with the novel coronavirus. The initiative will also have a diagnostic support system for all necessary tests, including imaging, such as computed tomography. The hospital will be coordinated by the National Institute of Infectious Diseases Evandro Chagas (INI/Fiocruz), the reference unit of the Foundation for clinical research and specialized care in infectious diseases, which already acts as a reference for Covid-19. The new space will be part of the Solidarity clinical trial, which is coordinated by Fiocruz in Brazil.

---

## Fiocruz is designated as reference institution in Covid-19 in the Americas for the WHO



The Laboratory for Respiratory Viruses and Measles of the Oswaldo Cruz Institute (IOC/Fiocruz) has been nominated Reference Laboratory of the World Health Organization (WHO) for Covid-19 in the Americas. After the formalization of the agreement between WHO and Fiocruz, the unit will now begin to make confirmatory tests for the disease in the region, and will also join the WHO network of laboratory specialists for Covid-19.

---

## MonitoraCovid-19 shows that deaths double every 5 days



The tool, developed by Fiocruz, shows that number of deaths caused by Covid-19 has doubled every 5 days in Brazil, on average. In the United States and in Ecuador, the interval necessary for this duplication is an average of 6 days. In Italy and in Spain, 8 days.

---

## Report assesses dissemination of Covid-19 among indigenous population



As the disease moves to smallest cities and the countryside, an increase in the rate of indigenous populations at high risk is also expected. This population is historically marked by the impact of epidemics and needs special attention as it already faces other vulnerabilities.

---

## Fiocruz becomes part of a Coalition to accelerate research on covid-19



The initiative of more than 70 scientists and institutions of 30 countries aims to guarantee access to advances in the research to developing countries and vulnerable populations, where the virus may cause serious problems in health systems that are already fragile.

---

## Fiocruz will be producing 11 million molecular tests



As its production capacity increases, Fiocruz will step up from about 60,000 tests produced in March to 1.2 million tests in April and 2.4 million in May. Between June and September, 2 million tests will be produced per month, making a total of 11 million molecular tests delivered to the Ministry of Health.

---

## Fiocruz launches a partnership program for actions against Covid-19



'United against Covid-19' is a channel for companies, organizations and individuals interested in being part of the network of supporters of initiatives developed by the institution, all over the country, to face this public health emergency.

---

### Fiocruz takes part in WHO meeting to fight the pandemic

Fiocruz president is one of the the global health leaders taking part on a weekly meeting to discuss how countries are dealing with the pandemic. The aim is to share their experiences and to create guidelines for the efforts against Covid-19.

---

### High doses of chloroquine are not indicated by CloroCovid-19

The trial is conducted by more than 70 researchers, with the participation of Fiocruz, and aims to evaluate the safety and efficacy of two different doses of drugs in critically ill patients. The initial results were published in the JAMA Network Open.

---

### Fiocruz investigates the action of anti-retrovirals against Covid-19

A study has found that the drug Atazanavir was able to inhibit viral replication in vitro and to reduce the production of proteins that are related to the inflammatory process in the lungs.

---

### Transmission of Covid-19 may have begun in November

Fiocruz researchers studied the genetic characteristics of the new coronavirus to analyze its dispersion and the beginning of the outbreak.

---

### ReBEC accelerates registries for clinical research on Covid-19

Scientists all over the world will be able to have quick access to the modeling of ongoing studies.

---

### Journal implements 'fast track' for studies on Covid-19

Memórias do Instituto Oswaldo Cruz is one of the oldest and most respected scientific journals in Latin America.

---

### Fiocruz HUB at the TGHN highlights Fiocruz actions

The Fiocruz Hub at the Global Health Network launched a hotsite, gathering the main institution's information and resources regarding the Covid-19.

## Links relacionados:

▶ [Fiocruz Global Health Center](#)

---

### Fiocruz International News

Bimonthly report of the Fiocruz Global Health Center (Cris/Fiocruz), edited by the Fiocruz Coordination of Social Communication

[Masthead](#) | [cancel subscription](#)

CRIS - Center for International  
Relations in Health

▶ [portal.fiocruz.br/en/cris](http://portal.fiocruz.br/en/cris)



Ministério da  
Saúde